CRA consultants assessed whether disputed representations of bioequivalence significantly affected sales of the branded product. The evaluation included consideration of distribution channels, purchase timing, and the effect of payor control mechanisms on product uptake and sales. The case ultimately resulted in a settlement.
IP Literature Watch: January 2023
In this month’s IP Literature Watch we include a chapter discussing the current state of legal, economic, and policy research on standard-essential patents and...